Mankind Pharma Ltd. · NSE:MANKIND
Mankind Pharma — Investor Presentation (October 2026)
27 slides from Mankind Pharma's investor presentation, Oct 27, 2026
Slide 1: Exchange filing cover letter: Investor Presentation
October 27, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Sub.: Investor Presentation Ref.: Regulation 30 & 51 o
Slide 2: Mankind Pharma Analyst / Investor Meet October 2026
A N A LY S T / I N V E S T O R M E E T Mankind Pharma October 2026
Slide 3: Our DNA | Evolution 1995 – 2026
Our DNA | Evolution 1995 – 2026 1995–2002 2002–2005 2007 2020–2022 2023 2024–2026 FOUNDATION METROS & CHRONIC BRAND MANKIND SPECIALTY PUBLIC LISTING COMPLEX & GLOBAL • Started from small • Metros and Tier-1 • Entered Consumer • Specialty divisions: • Listed on NSE & BSE • BSV acquisition towns and G
Slide 4: Mankind Today | FY26 at a glance
Mankind Today | FY26 at a glance Youngest ₹14,278 Cr 18.1% company in the IPM top 5 FY26 revenue Revenue CAGR, FY21–26 MARKET LEADERSHIP #1 #4 4 22 Prescription rank for 9 IPM rank by value Consumer brands ranked Brand families > ₹100 Cr years #1 COMMERCIAL REACH 5 lakh+ 18,500+ 17,600+ 84% Doctors
Slide 5: R&D | From Fixed-Dose Combination to novel molecules
R&D | From Fixed-Dose Combination to novel molecules R&D JOURNEY 2012 2018–19 2024 FY26 First R&D centre First in India Biologics platforms Towards innovation IMT Manesar, Haryana Dydrogesterone developed in- BSV – recombinants Own NCE house (Dydroboon) GPR-119 in Phase II JAK inhibitor in Phase I T
Slide 6: Manufacturing | From third-party to ~75% in-house
Manufacturing | From third-party to ~75% in-house MANUFACTURING EVOLUTION 1995–2001 Build-out Global quality Today · FY26 32 manufacturing Asset-light start facilities 7 plants ~75% in-house 100% third-party manufacturing in Built across USFDA-approved Of manufacturing the first 6–7 years Himachal P
Slide 7: FY24 – FY26 | Transformation
FY24 – FY26 | Transformation KEY INITIATIVES PORTFOLIO Leadership & Re-energised Doctor BSV ACQUISITION · FY25 Technology talent field force engagement Development and acquisition New KRA & incentive Optimised engagement Extensive use in the field • High-entry barrier portfolio framework strategy &
Slide 8: Outlook Ahead | Outperform IPM
OUTLOOK AHEAD | Outperform IPM EIGHT PILLARS OF GROWTH PILLAR 1 PILLAR 5 More brands above ₹50 / Chronic & Specialty Chronic share ~39% → ~50% Good to Great Brands ₹100 / ₹200 Cr PILLAR 2 • Cardio • GP Division PILLAR 6 • Gastro • Dental New Divisions • Cosmetology Consumer Healthcare Transform • Ge
Slide 9: Pillar 1 | Chronic & Specialty
Pillar 1 | Chronic & Specialty CHRONIC SHARE OF SALES From GPs -> CPs -> Super- Specialists ~50% 39% HOW WE STARTED WHAT WE ADDED 28% Combihale + Symbicort – 44% Cold & cough + Inhalers YoY, 3x IPM 1% Oral anti-diabetic + Insulin Nobeglar – 40% YoY growth FY04 FY18 FY26 FY30E 1 lac value Hypertensio
Slide 10: New Launches | Recent wins and the next wave
New Launches | Recent wins and the next wave SUCCESSFUL RECENT LAUNCHES Vonalong Nurokind HS PFS AdvaUD DynaDuo Vonoprazan Mecobalamin Pre-filled syringe Nor-Ursodeoxycholic Acid Empagliflozin + Linagliptin IQVIA RANK MARKET SHARE IQVIA RANK MARKET SHARE IQVIA RANK MARKET SHARE IQVIA RANK MARKET SHA
Slide 11: Pillar 5 | Big Brands Getting Bigger
Pillar 5 | Big Brands Getting Bigger BRAND FAMILIES BY SIZE ₹500 CR+ BRANDS (FY26) Sales band FY21 FY26 Added CAGR FY21–26 Telmikind ₹783 Cr 20% FY26 growth > ₹500 Cr 0 3 +3 14.4% Nurokind ₹667 Cr 8% FY26 growth Manforce ₹647 Cr 12% > ₹200 Cr 7 13 +6 12.8% FY26 growth NEW ₹50 CR+ BRANDS IN FY26 > ₹1
Slide 12: Pillar 6 | Consumer Healthcare – From Sexual Wellness to Consumer Wellness
Pillar 6 | Consumer Healthcare – From Sexual Wellness to Consumer Wellness WHAT WE HAVE BUILT OUTLOOK · NEXT PHASE OF GROWTH 1 Leader in sexual wellness Scale consumer healthcare #1 Manforce Condoms – 28% share; strengthened flavoured range in general trade led by consumer wellness and new-age chann
Slide 13: Pillar 7 | BSV – High-Barrier Specialty
Pillar 7 | BSV – High-Barrier Specialty #1 #1 / #2 ~37K ~88% Gynaecology rank in India* In 9 key brand families Gynaecologists covered IVF centre coverage HIGH-BARRIER BRANDS & PLATFORMS FUTURE OUTLOOK Anti-D (recombinant) • Focus on high revenue growth First novel biologic from India; 100% market s
Slide 14: Pillar 8 | Capital Allocation
Pillar 8 | Capital Allocation DEBT TRAJECTORY (₹ CR) CAPITAL ALLOCATION ROADMAP FINANCIAL DISCIPLINE Higher growth ~10,000 1 Deleverage Outperformance vs IPM ~75% lower Acquisition debt repaid by 2028* Increasing gross margins Rising chronic share 2 Growth capex Manufacturing – biologics, etc. Impro
Slide 15: Every Strategy Has an Expiry Date.
“Every Strategy Has an Expiry Date.” Mankind Pharma
Slide 16: Strategic Acquisition of Armed Cell Therapeutics
Strategic Acquisition “Every Strategy Has an Expiry Date.” of Armed Cell Therapeutics
Slide 17: Innovative Bets | ACTx: Next-Generation CAR-T
Innovative Bets | ACTx: Next-Generation CAR-T €48 Mn 70% 30% NHL & SCLC To be paid in tranches stake in ACTx, Belgium Retained & co-invest by lead programmes founders RIGHT DIRECTION Transformative Oncology therapy Armed CAR-T Multi-Target In-Vivo Armed CAR-T Not a startup – backed by Mankind’s scal
Slide 18: Armed Cell Therapeutics | Leadership Profile
Armed Cell Therapeutics | Leadership Profile Key Founding Team: Deep, Proven Biotech Leadership Paul Stoffels, MD Prof. John Mellors, MD Peter Verhaeghe Willemijn Kremer, MD Founder and Chair of the Board Founder, Chief Scientific Officer and Founder, Board member and Founder and CEO Board member Co
Slide 19: The Rising Cancer Burden
The Rising Cancer Burden Cancer is growing faster than health systems can absorb 20M 35M 1.5M $252B new cancer cases globally new cases expected by new cancer cases in India global oncology spending every year 2050, up 77% in 2024 in 2024, rising to $441B by 2029 Cancer remains an area of huge unmet
Slide 20: Cell and Gene Therapy | The Next Frontier
Cell and Gene Therapy | The Next Frontier Each wave of cancer treatment has added precision and value 1940s 2000s 2011 2013 2014 2017 Next Chemotherapy Targeted Checkpoint Antibody drug T cell engagers CAR T cell therapy In vivo CAR T therapies inhibitors conjugates (bispecifics) Broad and toxic Sma
Slide 21: Why CAR T | Reprogramming Your Own T Cells to Fight Cancer
Why CAR T | Reprogramming Your Own T Cells to Fight Cancer CAR T: one treatment, lasting remissions How CAR T cells work One shot A single infusion instead of continuous treatment The patient's own T cells are engineered to recognize cancer cells, bind to them and kill them. Deep responses The highe
Slide 22: Ex Vivo vs In Vivo | Solving for Scalability and Access
Ex Vivo vs In Vivo | Solving for Scalability and Access In vivo CAR T: from a complex process to a simple injection Ex vivo CAR T today In vivo CAR T: the aim Patient's cells collected No cell collection Weeks of manufacturing Off the shelf product per patient Chemotherapy beforehand Potentially no
Slide 23: Precedent Transactions | Validation for In Vivo CAR T
Precedent Transactions | Validation for In Vivo CAR T Strong strategic interest in in vivo CAR T Eli Lilly AbbVie AstraZeneca Gilead's Kite Kelonia Therapeutics Umoja Biopharma EsoBiotec Interius BioTherapeutics Up to $7B Up to $1.4B Up to $1B $350M Acquisition Oncology partnership Acquisition Acqui
Slide 24: Mankind's Approach | Differentiated Science and a Proven Team
Mankind's Approach | Differentiated Science and a Proven Team ACT's next generation CAR T, built to deliver durable remissions at scale 01 02 03 04 05 Multi targeting Armed Highest unmet In vivo focus Proven team need Reduces antigen Improves T cell Hematological and Aims to streamline The scientist
Slide 25: Beyond Mono Targeting | Multi Targeting and Armed CAR T
Beyond Mono Targeting | Multi Targeting and Armed CAR T MULTI Multi targeting versus mono ARMED Improving T cell fitness, persistence targeting and function Mono targeting Multi targeting Svoboda et al., Enhanced CAR T Cell Therapy for Lymphoma after Previous Failure, NEJM 2025 Reduces antigen escap
Slide 26: ACT Pipeline | Five Next Generation Global CAR T Programs
ACT Pipeline | Five Next Generation Global CAR T Programs Two lead programs focusing on non Hodgkin lymphoma and small cell lung cancer Program Area Discovery Preclinical Phase 1 Hemato oncology: Non Hodgkin LEAD 1 biCAR T, armed Preparing for first in human studies lymphoma Solid tumor: Small cell
Slide 27: Thank You
Thank You www.mankindpharma.com
Mankind Pharma — Investor Presentation (October 2026) on 6ix